Overview

Nova Satra Dx is a molecular diagnostics company committed to empowering patients and physicians through the research, development and commercialisation of blood-based tests that provide rapid and accurate detection of cancer based on Asian-specific epigenetic biomarkers.

 

The company is developing a pipeline of tests based on validated technology, the NovoTect™ technology, to address unmet medical needs in cancer diagnosis specifically for Asian patient populations. Nova Satra’s development pipeline includes molecular diagnostics tests for breast, colon, lung, prostate and stomach cancers.

The company’s first test, NovoTect™ Bc for the diagnosis of breast cancer, is the first ever test that stratifies Asian patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity. Nova Satra has completed validation trials for NovoTect™ Bc in collaboration with top medical institutions in Singapore and Malaysia, and is finalising plans to launch the test throughout Asia Pacific.

The first diagnostic tests to screen for Asian-specific epigenetic biomarkers.
NovoTect™ Bc is the first ever breast cancer diagnostic test that stratifies patients regardless of sub-type and stage of breast cancer with high specificity and sensitivity.